PSMB8 [The Human Chemical-Genetic Interaction Map Project]

This page is read only. You can view the source, but not change it. Ask your administrator if you think this is wrong.
======= PSMB8 =======


== Gene Information ==
  * **<color #00a2e8>Official Symbol</color>**: PSMB8
  * **<color #00a2e8>Official Name</color>**: proteasome 20S subunit beta 8
  * **<color #00a2e8>Aliases and Previous Symbols</color>**: N/A
  * **<color #00a2e8>Entrez ID</color>**: [[https://www.ncbi.nlm.nih.gov/gene/?term=5696|5696]]
  * **<color #00a2e8>UniProt</color>**: [[https://www.uniprot.org/uniprot/P28062|P28062]]
  * **<color #00a2e8>Interactions</color>**: [[https://thebiogrid.org/search.php?search=PSMB8&organism=9606|BioGRID]]
  * **<color #00a2e8>PubMed articles</color>**: [[https://www.ncbi.nlm.nih.gov/pubmed/?term=gene%20PSMB8|Open PubMed]]
  * **<color #00a2e8>OMIM</color>**: [[https://omim.org/entry/177046|Open OMIM]]

== Function Summary ==
  * **<color #00a2e8>Entrez Summary</color>**:  The proteasome is a multicatalytic proteinase complex with a highly ordered ring-shaped 20S core structure. The core structure is composed of 4 rings of 28 non-identical subunits; 2 rings are composed of 7 alpha subunits and 2 rings are composed of 7 beta subunits. Proteasomes are distributed throughout eukaryotic cells at a high concentration and cleave peptides in an ATP/ubiquitin-dependent process in a non-lysosomal pathway. An essential function of a modified proteasome, the immunoproteasome, is the processing of class I MHC peptides. This gene encodes a member of the proteasome B-type family, also known as the T1B family, that is a 20S core beta subunit. This gene is located in the class II region of the MHC (major histocompatibility complex). Expression of this gene is induced by gamma interferon and this gene product replaces catalytic subunit 3 (proteasome beta 5 subunit) in the immunoproteasome. Proteolytic processing is required to generate a mature subunit. Two alternative transcripts encoding two isoforms have been identified; both isoforms are processed to yield the same mature subunit. [provided by RefSeq, Jul 2008]. 
  * **<color #00a2e8>UniProt Summary</color>**:  The proteasome is a multicatalytic proteinase complex which is characterized by its ability to cleave peptides with Arg, Phe, Tyr, Leu, and Glu adjacent to the leaving group at neutral or slightly basic pH. The proteasome has an ATP-dependent proteolytic activity. This subunit is involved in antigen processing to generate class I binding peptides. Replacement of PSMB5 by PSMB8 increases the capacity of the immunoproteasome to cleave model peptides after hydrophobic and basic residues. Acts as a major component of interferon gamma-induced sensitivity. Plays a key role in apoptosis via the degradation of the apoptotic inhibitor MCL1. May be involved in the inflammatory response pathway. In cancer cells, substitution of isoform 1 (E2) by isoform 2 (E1) results in immunoproteasome deficiency. Required for the differentiation of preadipocytes into adipocytes. {ECO:0000269|PubMed:16423992, ECO:0000269|PubMed:19443843, ECO:0000269|PubMed:21881205, ECO:0000269|PubMed:8163024}.

<button type='primary' size='sm' modal='Pfam_Domains'>Pfam Domains</button>
<button type='primary' size='sm' modal='GO_terms'>GO Terms</button>


<modal id='Pfam_Domains' size='lg' title='Pfam Domains'>
|Proteasome|
</modal>

<modal id='GO_terms' size='lg' title='GO Terms'>
|spermatoproteasome complex|
|proteasome core complex, beta-subunit complex|
|threonine-type endopeptidase activity|
|proteasome core complex|
|proteasomal ubiquitin-independent protein catabolic process|
|proteasome complex|
|regulation of cellular amino acid metabolic process|
|cellular response to type I interferon|
|type I interferon signaling pathway|
|response to type I interferon|
|regulation of hematopoietic stem cell differentiation|
|antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-dependent|
|endopeptidase activity|
|regulation of transcription from RNA polymerase II promoter in response to hypoxia|
|antigen processing and presentation of exogenous peptide antigen via MHC class I|
|regulation of cellular amine metabolic process|
|NIK/NF-kappaB signaling|
|anaphase-promoting complex-dependent catabolic process|
|regulation of hematopoietic progenitor cell differentiation|
|negative regulation of G2/M transition of mitotic cell cycle|
|SCF-dependent proteasomal ubiquitin-dependent protein catabolic process|
|interleukin-1-mediated signaling pathway|
|Wnt signaling pathway, planar cell polarity pathway|
|antigen processing and presentation of peptide antigen via MHC class I|
|negative regulation of cell cycle G2/M phase transition|
|fat cell differentiation|
|regulation of establishment of planar polarity|
|stimulatory C-type lectin receptor signaling pathway|
|innate immune response activating cell surface receptor signaling pathway|
|regulation of stem cell differentiation|
|tumor necrosis factor-mediated signaling pathway|
|regulation of transcription from RNA polymerase II promoter in response to stress|
|regulation of DNA-templated transcription in response to stress|
|non-canonical Wnt signaling pathway|
|positive regulation of canonical Wnt signaling pathway|
|regulation of cellular ketone metabolic process|
|Fc-epsilon receptor signaling pathway|
|negative regulation of canonical Wnt signaling pathway|
|cellular response to interleukin-1|
|T cell receptor signaling pathway|
|antigen processing and presentation of exogenous peptide antigen|
|positive regulation of Wnt signaling pathway|
|regulation of mRNA stability|
|regulation of morphogenesis of an epithelium|
|antigen processing and presentation of exogenous antigen|
|regulation of RNA stability|
|cellular response to hypoxia|
|antigen processing and presentation of peptide antigen|
|regulation of G2/M transition of mitotic cell cycle|
|cellular response to decreased oxygen levels|
|response to interleukin-1|
|regulation of mRNA catabolic process|
|negative regulation of Wnt signaling pathway|
|regulation of cell cycle G2/M phase transition|
|negative regulation of mitotic cell cycle phase transition|
|cellular response to oxygen levels|
|antigen processing and presentation|
|negative regulation of cell cycle phase transition|
|innate immune response-activating signal transduction|
|cellular response to tumor necrosis factor|
|Fc receptor signaling pathway|
|regulation of animal organ morphogenesis|
|activation of innate immune response|
|response to tumor necrosis factor|
|regulation of canonical Wnt signaling pathway|
|protein deubiquitination|
|antigen receptor-mediated signaling pathway|
|protein modification by small protein removal|
|protein polyubiquitination|
|negative regulation of mitotic cell cycle|
|proteasome-mediated ubiquitin-dependent protein catabolic process|
|negative regulation of cell cycle process|
|regulation of mRNA metabolic process|
|positive regulation of innate immune response|
|response to hypoxia|
|proteasomal protein catabolic process|
|response to decreased oxygen levels|
|cell-cell signaling by wnt|
|Wnt signaling pathway|
|regulation of Wnt signaling pathway|
|post-translational protein modification|
|positive regulation of response to biotic stimulus|
|MAPK cascade|
|response to oxygen levels|
|signal transduction by protein phosphorylation|
|regulation of mitotic cell cycle phase transition|
|regulation of endopeptidase activity|
|regulation of small molecule metabolic process|
|cell surface receptor signaling pathway involved in cell-cell signaling|
|regulation of peptidase activity|
|regulation of cell cycle phase transition|
|immune response-activating cell surface receptor signaling pathway|
|regulation of hemopoiesis|
|regulation of innate immune response|
|positive regulation of defense response|
|immune response-regulating cell surface receptor signaling pathway|
|positive regulation of multi-organism process|
|regulation of response to biotic stimulus|
|posttranscriptional regulation of gene expression|
|ubiquitin-dependent protein catabolic process|
|modification-dependent protein catabolic process|
|modification-dependent macromolecule catabolic process|
|immune response-activating signal transduction|
|negative regulation of cell cycle|
|proteolysis involved in cellular protein catabolic process|
|immune response-regulating signaling pathway|
|positive regulation of response to external stimulus|
|cellular protein catabolic process|
|regulation of mitotic cell cycle|
|activation of immune response|
|cytokine-mediated signaling pathway|
|protein catabolic process|
|protein ubiquitination|
|viral process|
|regulation of proteolysis|
|regulation of cell cycle process|
|regulation of defense response|
|innate immune response|
|protein modification by small protein conjugation|
|regulation of multi-organism process|
|symbiotic process|
|interspecies interaction between organisms|
|regulation of cellular catabolic process|
|positive regulation of immune response|
|cellular macromolecule catabolic process|
|defense response to other organism|
|protein phosphorylation|
|protein modification by small protein conjugation or removal|
|regulation of catabolic process|
|cellular response to cytokine stimulus|
|macromolecule catabolic process|
|organonitrogen compound catabolic process|
|regulation of anatomical structure morphogenesis|
|regulation of response to external stimulus|
|response to cytokine|
|cell-cell signaling|
|regulation of immune response|
|positive regulation of immune system process|
|response to abiotic stimulus|
|regulation of cell cycle|
|negative regulation of signal transduction|
|proteolysis|
|regulation of hydrolase activity|
|transmembrane transport|
|phosphorylation|
|response to other organism|
|response to external biotic stimulus|
|response to biotic stimulus|
|defense response|
|negative regulation of cell communication|
|negative regulation of signaling|
|regulation of response to stress|
|negative regulation of response to stimulus|
|positive regulation of signal transduction|
|regulation of immune system process|
|intracellular signal transduction|
|cellular response to stress|
|organic substance catabolic process|
|cellular catabolic process|
|regulation of cell differentiation|
|positive regulation of cell communication|
|positive regulation of signaling|
|immune response|
</modal>
\\

 === CRISPR Data ===
<button type='primary' size='small' modal='Compound_Hit'>Compound Hit</button>
<button type='primary' size='small' modal='Most_Correlated_Genes'>Most Correlated Genes in Chemogenomics</button>
<button type='primary' size='small' modal='Essential_Avana'>Tissues where Essential in the Avana Dataset (DepMap 20Q1)</button>

<modal id='Compound_Hit' size='lg' title='Compound Hit'>
^Screen^Score^
|[[:results:exp6|Bortezomib 0.005μM R00 exp6]]|-6.68|
|[[:results:exp416|Tubacin 1.6μM R07 exp416]]|-4.01|
|[[:results:exp450|Artemisinin 50μM R08 exp450]]|-3.9|
|[[:results:exp320|ABT-702 5μM plus CoCl2 18μM R07 exp320]]|-2.81|
|[[:results:exp417|Tubastatin-A 2.5μM R07 exp417]]|-2.77|
|[[:results:exp354|Diepoxybutane 3μM R07 exp354]]|-2.74|
|[[:results:exp7|Bortezomib 0.05μM R00 exp7]]|-2.65|
|[[:results:exp312|2-Methoxyestradiol 0.55 to 1μM on day4 R07 exp312]]|-2.58|
|[[:results:exp346|CoCl2 18μM R07 exp346]]|-2.47|
|[[:results:exp525|Sulforaphane 9μM R08 exp525]]|-2.45|
|[[:results:exp84|UM0125461 0.74μM R02 exp84]]|-2.4|
|[[:results:exp67|BVD-523 15μM R02 exp67]]|-2.31|
|[[:results:exp360|Genistein 15μM R07 exp360]]|-2.16|
|[[:results:exp488|Hippuristanol 0.12μM R08 exp488]]|-2.13|
|[[:results:exp460|BML-284 0.09μM R08 exp460]]|-2.12|
|[[:results:exp59|UMK57 1μM R01 exp59]]|-2.11|
|[[:results:exp103|Taxol 0.004μM R03 exp103]]|-2.02|
|[[:results:exp459|Bleomycin 5μM R08 exp459]]|-2.01|
|[[:results:exp526|Sulforaphane 9μM R08 exp526 no dilution day6]]|-1.99|
|[[:results:exp34|Rotenone 20μM R00 exp34]]|-1.97|
|[[:results:exp99|NFN1 0.4μM R03 exp99]]|-1.94|
|[[:results:exp162|BI-D1870 2μM R04 exp162]]|-1.89|
|[[:results:exp218|A-395 10μM R05 exp218]]|-1.86|
|[[:results:exp8|Brefeldin A 0.02μM R00 exp8]]|-1.8|
|[[:results:exp66|BI-D1870 3.15μM R02 exp66]]|-1.77|
|[[:results:exp365|I-BRD9 4μM R07 exp365]]|-1.77|
|[[:results:exp342|Calcium Ionophore 0.4μM R07 exp342]]|-1.74|
|[[:results:exp294|Nutlin-3A 1.6μM R06 exp294]]|-1.73|
|[[:results:exp311|2-Methoxyestradiol 0.55 to 0.75μM  on day4 R07 exp311]]|-1.71|
|[[:results:exp274|Citral 50μM R06 exp274]]|2.01|
|[[:results:exp285|GW501516 25μM R06 exp285]]|2.21|
|[[:results:exp480|ETC-159 50μM R08 exp480]]|2.72|
</modal>

<modal id='Most_Correlated_Genes' size='lg' title='Most Correlated Genes in Chemogenomics'>
^Gene^Correlation^
|[[:human genes:p:psmb5|PSMB5]]|0.496|
|[[:human genes:p:psma2|PSMA2]]|0.423|
|[[:human genes:p:psmb6|PSMB6]]|0.422|
|[[:human genes:p:psmb7|PSMB7]]|0.411|
|[[:human genes:p:psma5|PSMA5]]|0.401|
</modal>

<modal id='Essential_Avana' size='lg' title='Tissues where Essential in the Avana Dataset (DepMap 20Q1)'>
Global Fraction of Cell Lines Where Essential: 0/739
^Tissue^Fraction Of Cell Lines Where Essential^
|1290807.0|0/1|
|909776.0|0/1|
|bile duct|0/28|
|blood|0/28|
|bone|0/26|
|breast|0/33|
|central nervous system|0/56|
|cervix|0/4|
|colorectal|0/17|
|esophagus|0/13|
|fibroblast|0/1|
|gastric|0/16|
|kidney|0/21|
|liver|0/20|
|lung|0/75|
|lymphocyte|0/16|
|ovary|0/26|
|pancreas|0/24|
|peripheral nervous system|0/16|
|plasma cell|0/15|
|prostate|0/1|
|skin|0/24|
|soft tissue|0/9|
|thyroid|0/2|
|upper aerodigestive|0/22|
|urinary tract|0/29|
|uterus|0/5|
</modal>

== Essentiality in NALM6  ==
    * **<color #00a2e8>Essentiality Rank</color>**: 10932
    * **<color #00a2e8>Expression level (log2 read counts)</color>**: 6.21 
<button type='primary' size='small' modal='Dist_expr'>Expression Distribution</button>
<modal id='Dist_expr' size='lg' title='PSMB8 Expression in NALM6 Cells: 6.21'>
{{:chemogenomics:nalm6 dist.png?nolink |}}
</modal>